The apparatuses and methods described herein relates generally to the field of active agent (drug) release from surgical grafts useful for soft tissue reconstruction, regeneration, or repair. More particularly, described herein are surgical grafts for soft tissue repair that include an active agent that is released over time while advantageously matching the biomechanical properties of tissue during healing and recovery.

A method for embolization of a blood vessel in a body, wherein at least one gelling component is biocompatible, biodegradable, with radiopaque capability and in liquid form to be supplied to a blood vessel by means of a single or multi lumen microcatheter and forming once in contact with a gelling agent in situ a deformable solid matrix in the body. The microcatheter may be provided with a first lumen disposed inside a second lumen. The gelling agent may be supplied to the blood vessel before the gelling component. Therapeutic compositions may be supplied to the blood vessel through the microcatheter.

Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.

The present disclosure relates to a hydrogel comprising: hyaluronic acid, and liposomes physically crosslinked to hyaluronic acid, wherein said hydrogel encapsulates a cell type or a plurality of cell types. The hydrogel of the present disclosure shows a positive therapeutic effect in the treatment or therapy of multiple sclerosis. A pharmaceutical composition comprising a therapeutically effective amount of a hydrogel and a pharmaceutically acceptable excipient/carrier are also disclosed.

The present invention relates to novel therapeutic nanoparticles. In particular, the present invention is directed to nanoparticles associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) with angiogenesis-activating-agents, methods of synthesizing the same, devices or compositions comprising such nanoparticles, as well as systems and methods utilizing the nanoparticles (e.g., in therapeutic settings for enhancing and/or activating angiogenesis at targeted tissue region).

This invention relates to exosome compositions and methods of using them.

An intraocular lenses having a plurality of drug-containing microspheres attached to the intraocular lens. The intraocular lenses can be used for patients undergoing cataract surgery and reduces the need for recurrent surgery, follow-up treatment or postoperative eye-drops. Also provides a method for manufacturing such an intraocular lens and the use of an intraocular lens in the treatment of cataract.

The present invention is an inflatable balloon which is enclosed by an expandable cover which becomes increasingly porous/permeable during expansion. The balloon is coated or enclosed with a matrix which contains a pharmaceutically active agent. During expansion of the balloon, the pharmaceutically active agent is released or extruded through the expandable cover into a body cavity such as an artery or vein. The present invention also provides for a method of treating a disease or condition by delivering the inflatable balloon to a particular body cavity.

The present invention relates to novel therapeutic nanoparticles. In particular, the present invention is directed to nanoparticles associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) with angiogenesis-activating-agents, methods of synthesizing the same, devices or compositions comprising such nanoparticles, as well as systems and methods utilizing the nanoparticles (e.g., in therapeutic settings for enhancing and/or activating angiogenesis at targeted tissue region).

Provided herein are compositions for treating biofilm-derived infections include a cis-monounsaturated fatty acid solubilized in a solvent with a concentration in the range of about 100 ppm (parts per million) to about 1000 ppm, where the composition is configured to produce a bactericidal effect measured as a log reduction of colony forming units (CFU) of a bacteria of at least 1.0 when the composition is applied to a biofilm formed from the bacteria. Also provided are methods for treating the site of a biofilm-derived infection comprising applying a composition as disclosed herein to the site.